According to the CITIC Construction Investment Research Report, the In Vivo CART circuit is booming, and there have already been four MNC mergers and acquisitions in 2025. Specifically, In Vivo CART is divided into two technical routes, LNP and lentivirus. Both technology routes have significant characteristics. Looking at the LNP route, the drug showed rapid transfection and excellent targeting characteristics before clinical trials. In the lentiviral route, eSobiotec's BCMA In Vivo CART has shown very good early data in small groups of MM patients. Overall, In Vivo CART is developing rapidly, and subsequent developments are worth paying attention to.

According to the CITIC Construction Investment Research Report, the In Vivo CART circuit is booming, and there have already been four MNC mergers and acquisitions in 2025. Specifically, In Vivo CART is divided into two technical routes, LNP and lentivirus. Both technology routes have significant characteristics. Looking at the LNP route, the drug showed rapid transfection and excellent targeting characteristics before clinical trials. In the lentiviral route, eSobiotec's BCMA In Vivo CART has shown very good early data in small groups of MM patients. Overall, In Vivo CART is developing rapidly, and subsequent developments are worth paying attention to.